Trial · NCT01365676
GAMALINE®+HIPERICIN® for PMS Treatment and Vasomotor Symptoms
NCT01365676, Phase 3, Unknown, Phytopharm Consulting Brazil
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. GAMALINE®+HIPERICIN® for PMS Treatment and Vasomotor Symptoms. Trials, record NCT01365676. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01365676
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GAMALINE®+HIPERICIN® for PMS Treatment and Vasomotor Symptoms
- NCT number
- NCT01365676
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 240 participants, estimated
- Lead sponsor
- Phytopharm Consulting Brazil
- Conditions
- Premenstrual Syndrome, Uterus; Hemorrhage, Preclimacteric or Premenopausal
- Interventions
- GAMALINE® + HIPERICIN®, GAMALINE®
- First posted
- 2011-06-03
- Last updated
- 2011-12-06
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PMS calendar | 240 days | Evaluation will run daily during the 240 days, comparing the results before treatment \[60 days (T-2) and 30 days (T-1)\]. Starting point (T0) treatment/under prescription, till 180 days treatment (T6). |
| Primary | LAB Tests | T0 T1 and T6 | Blood sample tests before T0 (all arms), after T1 (30 days only for experimental group) and end of T6 (after 180 days of prescription for all arms) |
| Secondary | WHOQOL | 06 months | WHOQOL will be evaluated at T-2 and T6 where T-2 is at the first interview after inclusion and T6 is at the end point of treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01365676
GET https://conductscience.org/api/trials/v1/NCT01365676/registered